Prolia (Denosumab) for Giant Cell Tumor: Evidence Summary

The Brand Distinction Matters: Xgeva vs. Prolia

Denosumab is sold under two separate brand names with different doses, indications, and pricing. Confusing them can lead to significant clinical errors. Prolia delivers 60 mg of denosumab every six months for postmenopausal osteoporosis and bone loss during hormone ablation therapy [1]. Xgeva delivers 120 mg on a loading schedule followed by monthly injections, and it holds FDA approval for three indications: prevention of skeletal-related events in patients with bone metastases from solid tumors, hypercalcemia of malignancy refractory to bisphosphonates, and giant cell tumor of bone in adults and skeletally mature adolescents [2].

When patients or clinicians search for "Prolia for giant cell tumor," they are usually asking about denosumab broadly. The drug is the same monoclonal antibody. The formulation is not. Prolia at 60 mg given every six months would deliver one-quarter the monthly exposure of the Xgeva regimen used in GCTB trials. No published trial has evaluated Prolia-dose denosumab for giant cell tumor, and prescribing it at that dose for GCTB would be both off-label and pharmacologically insufficient based on available evidence [2]. The remainder of this article refers to denosumab at the Xgeva dose (120 mg) unless stated otherwise.

What Is Giant Cell Tumor of Bone?

Giant cell tumor of bone is a locally aggressive, rarely metastasizing neoplasm that accounts for roughly 5% of primary bone tumors [3]. It peaks in adults aged 20 to 40. The distal femur, proximal tibia, and distal radius are the most common sites. Histologically, the tumor contains neoplastic stromal cells that overexpress receptor activator of nuclear factor kappa-B ligand (RANKL), which recruits and activates osteoclast-like multinucleated giant cells responsible for bone destruction [4].

Before denosumab, the standard treatment was surgical curettage with or without adjuvant agents like polymethylmethacrylate cement or phenol. Recurrence rates after curettage ranged from 12% to 65% depending on the series and the anatomic site [3]. Some patients required en bloc resection or even amputation for tumors in challenging locations like the sacrum, pelvis, or spine. A drug that could shrink the tumor or convert it to a less destructive state before surgery represented a major therapeutic advance.

Mechanism of Action in GCTB

Denosumab is a fully human IgG2 monoclonal antibody that binds RANKL with high affinity, preventing it from activating the RANK receptor on osteoclast precursors [4]. In GCTB, the neoplastic stromal cells produce RANKL in abundance, driving the formation of the giant cells that destroy surrounding bone. By neutralizing RANKL, denosumab eliminates the giant cell population from the tumor within weeks.

Histologic studies of resected specimens after denosumab treatment show near-complete disappearance of giant cells, new woven bone formation within the tumor bed, and persistent stromal cells that no longer cause aggressive osteolysis [5]. This is not cytotoxic therapy. The stromal cells survive, which explains why tumors can recur after denosumab is discontinued.

Key Clinical Trial Evidence

The Open-Label Phase 2 Study (Chawla et al., 2013)

The largest prospective study of denosumab in GCTB enrolled 532 patients across two cohorts [6]. Cohort 1 included 169 patients with recurrent or unresectable GCTB. Cohort 2 included 263 patients with resectable GCTB where surgery would result in severe morbidity (joint resection, limb amputation, hemipelvectomy). Patients received denosumab 120 mg subcutaneously on days 1, 8, 15, and 29, then every 4 weeks, with daily calcium and vitamin D supplementation.

In Cohort 1, the primary endpoint was tumor response by modified RECIST criteria or histologic elimination of giant cells. Objective response occurred in 72% of patients. In Cohort 2, 96% of patients had no disease progression at a median follow-up of 13 months, and 74 of 100 patients (74%) who were originally planned for surgery either had their procedure downstaged or avoided surgery entirely [6].

The study's lead investigator, Dr. Sant P. Chawla of the Sarcoma Oncology Center, stated: "Denosumab provided clinically meaningful benefit by reducing surgical morbidity in the majority of patients who would have otherwise required mutilating procedures" [6].

Earlier Proof-of-Concept (Thomas et al., 2010)

The first published evidence came from a proof-of-concept phase 2 trial by Thomas and colleagues, which enrolled 37 patients with recurrent or unresectable GCTB [7]. At the 120 mg dose on the same loading and monthly schedule, 86% (30 of 35 evaluable patients) had a tumor response defined as either at least 90% elimination of giant cells on biopsy or no radiographic progression. Median time to response was approximately 3 months. This trial established the dosing regimen that Xgeva's approval was built on.

Long-Term Follow-Up Data

Rutkowski et al. published interim results from an open-label extension showing that patients treated for a median of 44 months maintained disease control, with an overall disease control rate above 95% [8]. The study also documented that 20 of 84 patients (24%) who underwent surgery after denosumab pretreatment experienced local recurrence, confirming that denosumab suppresses rather than cures the disease.

A retrospective multicenter analysis by Errani et al. (2018) reported local recurrence rates of 60% in patients who discontinued denosumab after surgery, compared with 17% in those who continued it as adjuvant therapy [9]. These numbers have driven ongoing debate about optimal treatment duration.

FDA Approval and Regulatory Status

The FDA granted Xgeva approval for GCTB on June 13, 2013, under a supplemental Biologics License Application. The approval was based on the two phase 2 studies described above [2]. The European Medicines Agency (EMA) followed with approval in July 2014. Both agencies specified the indication for adults and skeletally mature adolescents with GCTB that is unresectable, or where surgical resection is likely to result in severe morbidity.

Dr. Richard Pazdur, then director of the FDA's Office of Oncology Drug Products, noted at the time of approval: "Xgeva provides a new treatment option for patients with giant cell tumor of bone, particularly those who face disabling surgery" [2].

The GRADE evidence level for denosumab in GCTB is moderate. There are no randomized controlled trials, only single-arm phase 2 studies. The quality of evidence is downgraded by the absence of a comparator group but supported by consistent results across multiple cohorts, clear histologic response, and meaningful clinical endpoints such as surgical downstaging [10].

Dosing Protocol and Monitoring

The standard Xgeva regimen for GCTB starts with a loading phase: 120 mg subcutaneously on days 1, 8, 15, and 29 of the first cycle [2]. After loading, the dose continues at 120 mg every 28 days. All patients should take calcium 500 mg and vitamin D 400 IU daily (or more as needed to maintain serum calcium in the normal range).

Monitoring should include serum calcium before each dose for at least the first three months, then periodically. Serum phosphate levels should also be tracked because hypophosphatemia occurred in 32% of patients in the key trial [6]. Dental examinations before initiating treatment and avoidance of invasive dental procedures during treatment are recommended to reduce the risk of osteonecrosis of the jaw (ONJ).

There is no established optimal duration. The Xgeva label does not specify when to stop. Clinical practice varies from 6 months of neoadjuvant therapy before planned surgery to indefinite treatment in unresectable cases. Discontinuation requires close imaging surveillance because rebound osteolysis and tumor recurrence can occur within months of the last dose [9].

Safety Profile in GCTB Patients

Denosumab at 120 mg monthly carries a different safety profile than the osteoporosis dose. The most common adverse events in GCTB trials were fatigue (24%), limb pain (21%), nausea (19%), headache (15%), and hypophosphatemia (32%) [6]. Hypocalcemia occurred but was less frequent (5%) when calcium and vitamin D supplementation was maintained.

ONJ is the most significant serious risk. In the GCTB population, which tends to be younger and without cancer-related bone disease, the incidence was approximately 1% to 5% depending on treatment duration and dental comorbidities [8]. Risk increases with duration of therapy, poor oral hygiene, and concurrent dental surgery.

A phenomenon called "rebound hypercalcemia" has been reported after discontinuation. Case reports describe symptomatic hypercalcemia occurring 2 to 6 months after the last dose, particularly in adolescents and young adults [11]. The proposed mechanism involves sudden unopposed osteoclast activation after RANKL inhibition is withdrawn. This risk means that clinicians should monitor calcium levels for at least 6 months after stopping denosumab in GCTB patients.

Comparison With Surgical Management Alone

No randomized trial has directly compared denosumab pretreatment plus surgery against surgery alone. The available evidence comes from retrospective comparisons and historical controls. A systematic review by Tsukamoto et al. (2020) analyzed outcomes from 1,355 patients across 21 studies [12]. Patients who received neoadjuvant denosumab before curettage had local recurrence rates of approximately 20% to 29%, while historical curettage-alone series reported rates of 15% to 25% for primary tumors and 30% to 50% for recurrent tumors.

The finding that denosumab-treated patients had similar or slightly higher recurrence rates surprised many clinicians. One explanation is selection bias: patients offered denosumab had larger, more aggressive, or more anatomically challenging tumors. Another hypothesis is that denosumab alters the tumor's histologic interface, making the curettage margin harder to define because new bone fills the cavity and obscures the tumor boundary [12].

The National Comprehensive Cancer Network (NCCN) guidelines for bone cancer list denosumab as a recommended systemic therapy option for GCTB that is unresectable, metastatic, or where surgery would cause significant morbidity [10]. For resectable GCTB without anticipated morbidity, surgery remains first-line, and routine neoadjuvant denosumab is not recommended outside of clinical judgment.

Pediatric and Adolescent Considerations

The Xgeva label specifies that treatment for GCTB should only be given to skeletally mature adolescents, defined by at least one closed epiphysis confirmed on imaging [2]. GCTB is rare before skeletal maturity, but when it occurs in teenagers, denosumab presents a unique concern. RANKL inhibition during active bone modeling can impair normal skeletal development. Case reports have documented sclerotic metaphyseal bands ("zebra lines") in the long bones of adolescents treated with denosumab, reflecting disrupted bone remodeling during growth [13].

Rebound hypercalcemia is also more common and more severe in adolescents. A case series from Memorial Sloan Kettering documented symptomatic rebound in 4 of 12 adolescent patients within 4 months of discontinuation [11]. These patients required monitoring and, in some cases, bisphosphonate bridging therapy to manage the calcium surge.

When Prolia Dose Would Be Genuinely Off-Label

There are rare clinical scenarios where a clinician might consider denosumab at a dose lower than 120 mg for a GCTB-adjacent condition. For example, a patient with a small, indolent recurrence who cannot tolerate the full Xgeva dose might receive a reduced dose, though no published evidence supports this approach. Any use of Prolia (60 mg) for a giant cell tumor indication is definitively off-label, not supported by pharmacokinetic modeling, and should be avoided unless part of a formal clinical trial [2].

The cost difference between brands is also relevant. In the United States, Xgeva 120 mg costs approximately $1,900 to $2,300 per monthly injection before insurance, while Prolia 60 mg costs approximately $1,600 to $1,800 per semiannual dose [14]. Using the wrong formulation is not a cost-saving strategy; it is a dosing error.